D. Santos

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.

Michael L. Wang, Y. Oki, K. Young, 2016, The Lancet. Oncology.

Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.

C. Flowers, Linghua Wang, Xuelin Huang, 2022, The Lancet. Oncology.

Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma

Michael L. Wang, C. Flowers, Linghua Wang, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Michael L. Wang, Shaojun Zhang, Linghua Wang, 2019, Blood.

A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients

Jeffrey E. Lee, K. Hunt, J. Vauthey, 2022, Surgery open science.

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma

Michael L. Wang, C. Flowers, Shaojun Zhang, 2021, Nature Communications.

Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.

Michael L. Wang, C. Flowers, Shaojun Zhang, 2020, Blood advances.

B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Michael L. Wang, Shouhao Zhou, Sabah Kadri, 2017, Clinical Cancer Research.

Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-2 Clinical Trial

Michael L. Wang, C. Flowers, P. Jain, 2021, Blood.

B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Michael L. Wang, Shouhao Zhou, Sabah Kadri, 2017, Clinical Cancer Research.

Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial

Michael L. Wang, Linghua Wang, K. Patel, 2019, Blood.